幽门螺杆菌治疗药物研究进展  

Progress in Medications for Helicobacter pylori Treatment

作　　者：文睿 程天恒 王妮涵 王婷 杨华丽 刘洋[1] 程卯生[1] WEN Rui;CHENG Tianheng;WANG Nihan;WANG Ting;YANG Huali;LIU Yang;CHENG Maosheng(MOE Key Laboratory of Target-based Drug Design and Research,Shenyang Pharmaceutical University,Shenyang 110016,China)

机构地区：[1]沈阳药科大学制药工程学院,基于靶点的药物设计与研究教育部重点实验室,沈阳110016

出　　处：《中国药学杂志》2024年第18期1695-1704,共10页Chinese Pharmaceutical Journal

摘　　要：幽门螺杆菌(Helicobacter pylori,H.pylori)是一种定植于胃内,具有螺旋状结构的微需氧革兰阴性菌,1982年被首次发现,可以导致胃炎、消化性溃疡以及胃癌等疾病的发生。目前,幽门螺杆菌已经感染全球近半数人口,且随着抗生素的大量应用,幽门螺杆菌的耐药问题也愈发严重,亟需能够克服幽门螺杆菌耐药性的新治疗药物。这也促进了大量针对幽门螺杆菌治疗药物的开发,其中已进入临床在研阶段的药物包括以合成抗菌药为主的化学药物和以疫苗、益生菌为主的生物药物。本文简述了幽门螺杆菌的致病机制和治疗现状,对已上市和临床在研的幽门螺杆菌治疗药物进行了总结和评述,以期为后续的幽门螺杆菌治疗药物开发提供思路。Helicobacter pylori(H.pylori)is a microaerophilic,Gram-negative bacterium that colonizes the gastric mucosa and exhibits a distinctive spiral morphology.It was found to be involved in the development of diseases such as gastritis,peptic ulcers,and gastric cancer in 1982.Currently,H.pylori infection affects more than half of the global population,and the emergence of antibiotic resistance poses a significant challenge.Consequently,there is an urgent need for novel therapeutic agents capable of overcoming H.pylori resistance.This review provides a concise overview of the pathogenic mechanisms associated with H.pylori while summarizing and discussing both approved pharmaceuticals and investigational drugs targeting this bacterium,with the aim of facilitating the advancement of subsequent therapeutic agents targeting H.pylori.

关 键 词：幽门螺杆菌 耐药性 抗生素 幽门螺杆菌疫苗 益生菌 

分 类 号：R378[医药卫生—病原生物学]